News Across Medicine This Week - April 20, 2025 to April 27, 2025
April 27th 2025
What's new across the specialties? Take a quick look from select fields...
A Nutritionist Shares Insights
April 14th 2025
Ali Beckman, MS, RD, LD, CEDS-C, talks about psychiatry and how the role of nutrition.
Psychiatry in the News: Week of March 30th
April 4th 2025
A roundup of psychiatric news from around the globe for the week of March 30, 2025.
Taking a New 'Psyched Perspective' on the Field
April 2nd 2025
Frank A. Clark, MD, discusses his new "Psyched Perspectives" series on Psychiatric Times.
Eisenhower Fellowships Launches 2022 USA Justice Program With Psychiatric Fellow
August 29th 2022
Eisenhower Fellowships has launched its 2022 USA Justice Program with an inaugural cohort of 11 mid-career US professionals from a variety of fields, including psychiatry, to address issues in inequality.
Virtual Psychiatry is Here to Stay
August 22nd 2022
One psychiatrist considers the advantages of virtual psychiatric treatment for both patients and clinicians.
Trauma in Your DNA: Educator of the Year Lecture
August 17th 2022
Real true, posttraumatic stress disorder [PTSD] is going to have an impact, certainly on the next generation and maybe generations after that," said Rachel Yehuda, PhD.
Adhansia XR Is Granted a Controversial Approval for ADHD Treatment
April 22nd 2019
Adhansia XR, also known as methylphenidate hydrochloride, was given approval by the FDA for the treatment of ADHD. However, this approval has been met with some controversy.
SPN-812 Gains Another Positive Study for the Treatment of Adolescents with ADHD
January 28th 2019
In its third Phase III study, SPN-812 met its primary endpoint with positive results. Marking a major step for Supernus Pharmaceuticals novel ADHD treatment.<br />
Treatment for Depression Using mHealth Apps Is Proven to be Helpful
January 25th 2019
In today's world, so many people have mobile smartphones that mHealth apps seem a natural next step of healthcare. But until now, there hasn't been a study examining the efficacy of mHealth apps for the treatment of depression.
Phase 2 Study Results of Novel Investigational Agent for the Treatment of Schizophrenia Announced by Sunovion
January 24th 2019
A pivotal phase-2 study of a novel psychotropic agent for the treatment of patients with schizophrenia, met its primary endpoints for safety and efficacy.
Abnormal Response to Epstein-Barr Virus Found in Schizophrenia Patients
January 23rd 2019
A recent study from Johns Hopkins Medicine and Sheppard Pratt Health Systems shows a suprising connection between Schizophrenia and the Epstein-Barr Virus, aka mono.
Research Shows Untreated ADHD Reduces Life Expectancy
17 million people in the United States live with ADHD and not only is treatment essential, a new study shows that living without treatment will reduce life expectancy for patients.
FDA Reclassifies Some Electroconvulsive Therapy Devices to Lower Risk Category
The FDA published a final order requiring manufactures to file for a PMA for most uses of ECT devices. This order also reclassified ECT devices used in the treatment of catatonia or severe major depressive episodes.
Depression Screening Less Common for Men and Minorities
December 11th 2018
Depression screening is important in primary care, but according to new findings screening for depression is less common in men and minorities.
Brexanolone Reports Rapid, Durable Treatment for Post-Partum Depression
After a priority review granted in May, brexanolone has been proven to be a potentially rapid and durable treatment of post-partum depression (PPD) in new mothers.
Reduced Risk of Tardive Dyskinesia with 2nd-Generation Antipsychotics Re-Established
A recent meta analysis of the relationship between tardive dyskinesia and common antipsychotic medications re-established findings that 2nd-generation antipsychotics have a reduced risk of Tardive Dyskinesia.
